The estimated Net Worth of Jigar Raythatha is at least $3.13 Millón dollars as of 11 May 2020. Mr. Raythatha owns over 9,235 units of Constellation Pharmaceuticals Inc stock worth over $821,538 and over the last 6 years he sold CNST stock worth over $0. In addition, he makes $2,306,720 as President, Chief Executive Officer y Director at Constellation Pharmaceuticals Inc.
Jigar has made over 2 trades of the Constellation Pharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 9,235 units of CNST stock worth $50,885 on 11 May 2020.
The largest trade he's ever made was exercising 102,750 units of Constellation Pharmaceuticals Inc stock on 6 November 2019 worth over $566,153. On average, Jigar trades about 11,199 units every 19 days since 2018. As of 11 May 2020 he still owns at least 24,170 units of Constellation Pharmaceuticals Inc stock.
You can see the complete history of Mr. Raythatha stock trades at the bottom of the page.
Jigar Raythatha serves as President, Chief Executive Officer, Director of the Company. Mr. Raythatha previously served as chief business officer of Jounce Therapeutics, Inc., a biotechnology company, from December 2012 to February 2017, where he helped build the company from its inception to a publicly traded research and development organization. Previously, he served as our head of corporate development from March 2009 to February 2013, where he led business development, strategy and program and alliance management functions. Prior to serving as our head of corporate development, Mr. Raythatha joined Red Abbey Venture Partners, LLC in 2005 and served as a Kauffman fellow from 2005 to 2007, principal from 2007 to 2009 and venture partner in 2009. Prior to Red Abbey Venture Partners, Mr. Raythatha worked at Biogen Inc. from 1999 to 2003 in a variety of business development, commercial, and program management roles. He earned an M.B.A. from Columbia University and a B.A. in biochemistry and economics from Rutgers University.
As the President, Chief Executive Officer y Director of Constellation Pharmaceuticals Inc, the total compensation of Jigar Raythatha at Constellation Pharmaceuticals Inc is $2,306,720. There are no executives at Constellation Pharmaceuticals Inc getting paid more.
Jigar Raythatha is 43, he's been the President, Chief Executive Officer y Director of Constellation Pharmaceuticals Inc since 2017. There are 10 older and no younger executives at Constellation Pharmaceuticals Inc. The oldest executive at Constellation Pharmaceuticals Inc is James Audia, 64, who is the Director.
Jigar's mailing address filed with the SEC is C/O JOUNCE THERAPEUTICS, INC., 780 MEMORIAL DRIVE, CAMBRIDGE, MA, 02139.
Over the last 15 years, insiders at Constellation Pharmaceuticals Inc have traded over $36,293,867 worth of Constellation Pharmaceuticals Inc stock and bought 6,651,976 units worth $88,473,679 . The most active insiders traders include Peter Svennilson, Of The University Of Califo... y Anthony B Evnin. On average, Constellation Pharmaceuticals Inc executives and independent directors trade stock every 17 days with the average trade being worth of $4,934,940. The most recent stock trade was executed by Mark A Goldsmith on 4 March 2021, trading 14,987 units of CNST stock currently worth $509,408.
Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics that selectively modulate gene expression to address serious unmet medical needs in patients with cancer. The Company has a deep understanding of how epigenetic and chromatin modifications in cancer cells and in the tumor and immune microenvironment play a fundamental role in driving disease progression and drug resistance. Constellation is driving development of the BET inhibitor CPI-0610 for the treatment of myelofibrosis as well as the EZH2 inhibitor CPI-0209 for the treatment of solid tumors. The Company is also applying its broad research and development capabilities to explore other novel targets that directly and indirectly impact gene expression to fuel a sustainable pipeline of innovative small-molecule product candidates.
Constellation Pharmaceuticals Inc executives and other stock owners filed with the SEC include: